• Fenofibrate and the PPARα–YAP Axis

  2026-10-08

  Fenofibrate is a PPARα agonist that links lipid metabolism research with age-related liver biology. A 2025 mouse study reported comparable liver enlargement and PPARα–YAP signaling activation in adult and aging models, while product-level oncology findings remain preliminary and model-dependent.

• Sodium Chloride B7288: Evidence-Limited Overview

  2026-10-07

  Sodium chloride (NaCl) B7288 is listed by APExBIO as a 98% inorganic salt and laboratory reagent for broad aqueous research contexts. No matched paper evidence is available, so product-specific performance and application suitability remain unestablished.

• Protease Inhibitor Cocktail in hPSC-CM Research

  2026-10-07

  The Protease and Phosphatase Inhibitor Cocktail can support more defensible protein and phosphoprotein measurements in chamber-specific hPSC-cardiomyocyte research. This article connects EDTA-free sample preservation with the interpretation of right ventricular-like cardiomyocyte findings, while defining the product’s evidentiary limits.

• BPN-19186: Interpreting sEH–Nrf2 Evidence

  2026-10-06

  BPN-19186 is examined as a research candidate within the sEH–Nrf2–osteoclastogenesis framework. This article separates findings demonstrated by the osteoporosis study from hypotheses requiring independent target-engagement and pathway validation.

• ABT-888 (Veliparib) in DNA Damage Research

  2026-10-06

  ABT-888, also known as Veliparib, is a PARP1/2 inhibitor used in research on DNA damage responses, chemotherapy sensitization and cancer therapy resistance. Supplier-reported colorectal cancer findings support further study, while a recent acute leukemia investigation found that PARP inhibition did not significantly alter calicheamicin cytotoxicity, highlighting the importance of tumor context and evidence boundaries.

• GSK-923295: CENP-E Inhibitor Research Context

  2026-10-05

  GSK-923295 is a small-molecule CENP-E inhibitor used to interpret chromosome alignment, mitotic control, and cancer-cell responses. This overview compares supplier-reported biochemical, cell-line, and xenograft findings with recent evidence that CTCF maintains centromere function, emphasizing what can—and cannot—be concluded across these research contexts.

• How Dual-Action Inhibitors Reshape p38α Control

  2026-10-05

  A 2024 bioRxiv preprint reports that selected kinase inhibitors can both block p38α activity and accelerate its dephosphorylation by WIP1. Structural and biochemical evidence links this effect to an activation-loop conformation that exposes the regulatory phosphothreonine, suggesting a conformation-directed strategy for more durable and selective kinase inhibition.

• ABT-888 (Veliparib) in Translational DNA Repair Research

  2026-10-04

  A source-grounded perspective on ABT-888 (Veliparib), PARP-mediated DNA repair inhibition, chemotherapy and radiation sensitization, and the emerging relationship between PPP2R2A loss, replication stress, and CHK1 dependence.

• α-Bungarotoxin and the Logic of α7 Receptor Blockade

  2026-10-03

  α-Bungarotoxin is more than a receptor antagonist: it is a causal probe for testing whether α7 nicotinic acetylcholine receptor signaling connects cholinergic activity with inflammation, cell death, and tissue dysfunction. This article interprets recent preeclampsia-model findings while defining the translational limits of pharmacological blockade.

• Phenothiazines, ROS, and Macrophage Autophagy

  2026-10-02

  Qiu et al. show that phenothiazines strengthen macrophage antibacterial activity by coordinating reactive oxygen species accumulation, lysosomal activity, and autophagy. Inhibitor and scavenger experiments support a host-directed mechanism, while an in vivo Salmonella Typhimurium model indicates that perphenazine can reduce infection-associated lesions and inflammation.

• MitMAB for Endocytosis Research in Organoids

  2026-10-01

  MitMAB provides a practical way to test whether dynamin-dependent membrane scission contributes to extracellular vesicle uptake in polarized intestinal models. Its value is greatest when paired with region-specific organoids, matched vehicle controls, viability checks, and orthogonal trafficking readouts.

• Firefly Luciferase mRNA: Assay Workflows

  2026-10-01

  Build reproducible translation, transfection, cell viability, and imaging workflows with a capped, modified Firefly Luciferase mRNA reporter. The guide connects practical assay design with a human tripartite cell-free translation strategy, helping distinguish RNA delivery, transcript stability, and ribosome-dependent protein synthesis.

• Linagliptin (BI-1356): A Rigorous Assay Guide

  2026-09-30

  Linagliptin (BI-1356) is best understood as a DPP-4-directed pharmacological tool, not a substitute for NUAK inhibition. This guide explains how to position it responsibly in tau and Alzheimer’s disease experiments informed by p-tau Ser356 evidence.

• Sulfisomidine: hPON1 Assay Workflows

  2026-09-30

  Sulfisomidine, also known as sulfamethin, is a practical probe for mixed-type hPON1 inhibition and PABA-dependent antibacterial research. This workflow-focused guide covers stock preparation, kinetic experiment design, cross-domain applications, and troubleshooting for reproducible in vitro studies.

• EdU Imaging Kits (488) for S-Phase Assays

  2026-09-29

  EdU Imaging Kits (488) convert DNA replication into a high-contrast fluorescence readout without the DNA denaturation required by BrdU workflows. The assay is especially useful for connecting drug exposure to S-phase suppression, cell-cycle arrest, senescence, and apoptosis in cancer models.

8268 records 1/552 page Next 12345 下5页 Last page